Table 1.
Clinical features of the study population
| Included patientsa (N = 113, 76%) | Total (N = 149) | ||
|---|---|---|---|
| Age (years) | Median (Q1–Q3) | 67.0 (62.0, 73.0) | 67.0 (62.0, 74.0) |
| Sex | Male | 74 (65.5%) | 97 (65.1%) |
| Female | 39 (34.5%) | 52 (34.9%) | |
| Smoking | No | 13 (11.5%) | 19 (12.8%) |
| Former | 61 (54.0%) | 79 (53.0%) | |
| Yes | 39 (34.5%) | 51 (34.2%) | |
| ECOG-PS | 0 | 48 (42.5%) | 69 (46.3%) |
| 1–2 | 65 (57.5%) | 80 (53.7%) | |
| Histology | Non-squamous | 98 (86.7%) | 129 (86.6%) |
| Squamous | 15 (13.3%) | 20 (13.4%) | |
| PD-L1 | Negative | 38 (33.6%) | 38 (25.5%) |
| Positive | 75 (66.4%) | 75 (50.3%) | |
| Not available | – | 36 (24.2%) | |
| Extrathoracic sites | No | 44 (38.9%) | 62 (41.6%) |
| Yes | 69 (61.1%) | 87 (58.4%) | |
| N metastatic sites | 0–1 | 59 (52.2%) | 74 (49.7%) |
| 2–4 | 54 (47.8%) | 75 (50.3%) | |
| Treatment setting | 1 L | 50 (44.2%) | 50 (33.6%) |
| >1 L | 63 (55.8%) | 99 (66.4%) | |
| Follow-up (months) | Median (Q1–Q3) | 62.1 (59.4, 71.6) | 63.5 (60.5, 78.0) |
aIncluded patients refer to patients included in multivariate analyses, with all clinicopathological data available.